LY-354740 hydrate, > = 98 %(HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

LY-354740 hydrate has been used as a metabotropic glutamate receptor group II/III agonist to study its behavioral effectsof electric shock on Gammarus fossarum.

Biochem/physiol Actions

LY-354740 is a highly selective and potent agonist of group II mGlu (metabotropic glutamate) receptors. It displays antianxiety and antiaddictive activity in vivo. It?s orally and systemically active. It is anxiolytic and inhibits symptoms of morphine withdrawal in morphine-dependent mice.

Features and Benefits

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Glutamate Receptors (G Protein Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle